Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer

Journal of Clinical Oncology

Volumn 25, Issue 31, 2007, Pages 4961-4966

  Goss, Paul ^a   Bondarenko, Igor N ^a   Manikhas, Georgiy N ^a   Pendergrass, Kelly B ^a   Miller Jr , Wilson H ^a   Langecker, Peter ^a   Blanchett, Dennis ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATAMESTANE; LETROZOLE; TOREMIFENE;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT FAILURE;

AGED; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RECEPTORS, STEROID; TOREMIFENE; TRIAZOLES;

EID: 36849060326     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.5455     Document Type: Article

References (21)

1. Goss PE, Strasser K: Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19:881-894, 2001
2. Rose C, Mouridsen HT: Endocrine therapy of advanced breast cancer. Acta Oncol 27:721-728, 1988
3. Nabholtz A, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. J Clin Oncol 18:3758-3767, 2000
4. Bonneterre J, Thurlimann B, Robertson J, et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol 18:3748-3757, 2000
5. Bonneterre J, Buzdar A, Nabholtz JM, et al: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247-2258, 2001
6. Dirix J, Piccart MJ, Lohrisch C, et al: Efficacy of and tolerance to exemestane versus tamoxifen in first-line hormonal therapy of postmenopausal metastatic breast cancer patients: A European Organization for the Research and Treatment of Cancer Phase II Trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 20:29a, 2001 (abstr 114)
7. Buzdar A, Jonat W, Howell A, et al: Significant improved survival with Arimidex (anastrozole) vs megestrol acetate (MA) in postmenopausal advanced breast cancer: Updated results of two randomized trials. Proc Am Soc Clin Oncol 16:156a, 1997 (abstr 545)
8. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Cancer Group. J Clin Oncol 19:2596-2606, 2001
9. Mouridsen H, Gershanovich M, Sun Y, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109, 2003
10. Cole MP, Jones CTA, Todd IDH: A new antiestrogenic agent in late breast cancer: An early appraisal of ICI 46474. Br J Cancer 25:270-275, 1971
11. Brodie AMH, Schwarzel WC, Brodie HJ: Studies on the mechanism of estrogen biosynthesis in the rat ovary: 1. J Steroid Biochem 7:787-793, 1976
12. Lu Q, Yue W, Wang J, et al: The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res Treat 50:63-71, 1998
13. Santen RJ, Song RX, Zhang Z, et al: Adaptive hypersensitivity to estrogen: Mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocrine-Related Cancer 10:111-130, 2003
14. Masamura S, Santner Sj, Heitjan DF, et al: Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80:2918-2925, 1995
15. Baum M, Budzar AU, Cuzick J, et al: ATAC Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer - First results of the ATAC randomized trial. Lancet 359:2131-2139, 2002
16. Brodie A, Lu Q, Liu Y, et al: Aromatase inhibitors and their antitumor effects in model systems. Endocr Relat Cancer 6:205-210, 1999
17. di Salle E, Zaccheo T, Ornati G: Antiestrogenic and antitumor properties of the new triphenethylene derivative toremifene in the rat. J Steroid Biochem 36:203-206, 1990
18. Zaccheo T, Giudici D, Ornati G, et al: Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours. Eur J Cancer 27:1145-1150, 1991
19. National Cancer Institute: Common Toxicity Criteria, Version 2.0. Bethesda, MD, DCTD, NCI, NIH, DHHS, 1998
20. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
21. Powles TJ, Gordon C, Coombes RC: Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifenaminoglutethimide-danazol compared to tamoxifen used alone. Cancer Res 42:3458s-3460s, 1982